KA

Kineta, Inc. Common Stock
KA

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

KA was delisted on the 18th of September, 2024.

Back to rankings
 

About: Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Employees: 11

Healthcare Drug Manufacturers - General
Price charts implemented using Lightweight Charts™